Compare Sana Biotechnology Inc (SANA) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vipshop Holdings Ltd - ADR — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $1.03B), while Vipshop Holdings Ltd - ADR trades at $12.8 (market cap $6.20B). The key difference: Vipshop Holdings Ltd - ADR is far larger — about 6× Sana Biotechnology Inc's market cap, and Vipshop Holdings Ltd - ADR pays a 4.76% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | VIPS | |
|---|---|---|
Market Cap | $1.03B | $6.20B |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $20.68 |
52-Week Low | $2.68 | $12.51 |
Enterprise Value | $946.04M | $3.02B |
Dividend Yield | — | 4.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Vipshop Holdings trades at $13.03, down 1.29% on the day, with bearish technical signals dominating despite attractive valuation metrics. The company reported mixed Q2 2026 results with significant earnings misses, though maintains strong profitability with 9.82% net margin and 24.44% ROE. Recent institutional activity includes Nykredit A/S establishing a $2.35 million position in Q2 2026.
The stock presents a value opportunity with P/E of 4.21 and P/S of 0.41, but faces headwinds from declining revenue and challenging consumer sentiment. Analyst consensus leans bullish with 53.57% buy ratings, though technical indicators suggest near-term pressure. Key risks include Chinese consumer spending weakness and competitive pressures in e-commerce.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
